Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin

Neurocognitive Disorders Clinical Trial

— ATEPDIPSY  

Official title:

Contribution of Brain Positon Emission Tomography With 18 Flurodeoxyglucose Labelled With Fluorine 18 for the Differential Diagnosis of Cognitive Disorders of Psychiatric or Neurodegenerative Origin

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06463093
• Other study ID #: 2023PI120
• Status: Recruiting
• Start date: June 30, 2024
• Est. completion date: July 2, 2025

Study information

• Verified date: June 2024
• Source: Central Hospital, Nancy, France
• Contact: Antoine VERGER, MD, PhD
• Phone: 0383153911
• Email: a.verger[@]chru-nancy.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the research is to analyze whether 18F-FDG PET helps in the diagnosis and therefore in the management of the patient.

Description:

Neurocognitive disorder or Mild Cognitive Impairment corresponds to a decline in one or more cognitive functions; compared to the previous level of performance.

Indeed, the prevalence of neurodegenerative pathologies is estimated at more than one million according to Santé Publique France, due to the aging of the population. To be compared with the prevalence of the population suffering from a psychiatric disorder estimated at one in five people, or 13 million French people, in 2021.

With the increase in the prevalence of these two entities and their clinical entanglement, the question arises of the origin of neurocognitive disorders, is it a manifestation of a psychiatric pathology or a neurodegenerative pathology not yet diagnosed.

If this is the case, the patient's prognosis is modified with a pejorative evolution and a loss of autonomy which is to be anticipated. This delay deprives the patient and his family of interventions likely to alleviate behavioral disorders; maintain a level of autonomy compatible with life at home; alleviates the burden and improves the quality of life of caregivers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: July 2, 2025
• Est. primary completion date: July 2, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Adult patients with cognitive impairment

• Positron emission tomography with flurodeoxyglucose labeled with fluorine 18 carried out in the course of care

Exclusion Criteria:

• Patients objecting to the collection of their data

Related Conditions & MeSH terms

• Cognition Disorders
• Cognitive Dysfunction
• Neurocognitive Disorders

Locations

Country	Name	City	State
France	Nancy's hospital	Vandœuvre-lès-Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neuro cognitive disorders and disorders of neurodegenerative origin in psychiatric population	Change of the diagnosis before the PET and after the PET	one day